What the FDA decided on Mimrylo for Polycythemia vera
The FDA approved Mimrylo (rusfertide) for polycythemia vera. First hepcidin mimetic approved for polycythemia vera.
Who the Mimrylo decision matters to
Polycythemia Vera is a myeloproliferative neoplasm in which bone marrow produces too many red blood cells, leading to thick blood that carries oxygen less effectively and increases clot risk. Most patients have a mutation in the JAK2 gene.
While some people with PV have no symptoms, others experience fatigue, headaches, vision problems, and risk of blood clots and bleeding.
Prevalence: About 44 to 57 per 100,000 people in the US, from 2 large health plans in 2008 to 2010 (Mehta et al., Leukemia and Lymphoma 2014); median age of diagnosis is 65 years. See our full Polycythemia Vera page for current treatments, recruiting trials, and community resources.
How Mimrylo works
Mimrylo: injectable peptide that mimics hepcidin, the body's iron-regulating hormone, blocking the iron exporter ferroportin to limit the iron available for making red blood cells. Our full Mimrylo profile covers how it works, side effects in plain language, and its trial history.
Where Polycythemia Vera treatment stands today
Read our full Polycythemia Vera treatment summary
Research in Polycythemia Vera is expanding beyond traditional phlebotomy and aspirin toward targeted molecular therapies that address the underlying JAK2 mutations driving the disease. JAK2 inhibitors, HDAC inhibitors, and other innovative agents are being tested to reduce clot risk, lower disease burden, and improve quality of life for patients living with this condition.
Ongoing trials are examining how best to combine these therapies and how to use genetic and molecular testing to predict which patients need more intensive treatment. While phlebotomy and low-dose aspirin remain important foundational treatments, newer agents provide additional options, particularly for high-risk patients.
In August 2026 the FDA approved rusfertide (Mimrylo), a once-weekly injection under the skin that mimics hepcidin, the body's iron-regulating hormone, to treat erythrocytosis in adults with polycythemia vera. In its Phase 3 VERIFY trial, where it was added to usual care, 76.9% of patients no longer qualified for a phlebotomy during weeks 20 to 32, against 32.9% on placebo.
Discussing trial opportunities with your hematologist allows you to participate actively in decisions about treatment intensity and approach.
The Polycythemia Vera page has every treatment and trial →Meanwhile, 55 Polycythemia Vera studies are open or about to open
The FDA's decision does not end research on Polycythemia Vera. The most recently updated:
You'll hear about future FDA decisions and new recruiting trials for Polycythemia Vera. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
Has the FDA decided on Mimrylo?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: Takeda press release
What was Mimrylo approved for?
The FDA approved Takeda / Protagonist Therapeutics' NDA for Mimrylo in Polycythemia vera.
What to know: First hepcidin mimetic approved for polycythemia vera.
How it works: Injectable peptide that mimics hepcidin, the body's iron-regulating hormone, blocking the iron exporter ferroportin to limit the iron available for making red blood cells.
More: the Mimrylo drug page explains it in plain language.
Is there already an FDA-approved treatment for Polycythemia Vera?
Yes. Trial Friend's drug list includes 2 FDA-approved drugs for Polycythemia Vera.
Approved: Besremi (ropeginterferon alfa-2b-njft), Mimrylo (rusfertide).
Check: the Polycythemia Vera page also searches FDA drug labels for approved treatments.
What did the Mimrylo trials show?
VERIFY (NCT05210790) randomized 293 adults with polycythemia vera who needed frequent phlebotomies (at least 3 in 28 weeks or 5 in a year) despite standard care to Mimrylo or placebo for 32 weeks, added to their usual treatment. At the start, 44.7% were on phlebotomy alone and the rest also took hydroxyurea, interferon or ruxolitinib.
More: the Mimrylo drug page has the full trial history and sources.
What are the side effects of Mimrylo?
Mimrylo has no boxed warning and no contraindications. In the 32-week placebo-controlled part of the VERIFY trial, side effects more common than on placebo were injection site reactions (56% vs 33%), anemia (16% vs 4.1%), high platelet counts (8% vs 0.7%) and shortness of breath (8% vs 1.4%).
Most common: Injection site reactions (56% vs 33% on placebo), Anemia (16% vs 4.1%), High platelet count (8% vs 0.7%), Shortness of breath (8% vs 1.4%).
More: the Mimrylo drug page has the label's warnings in full.
How much will Mimrylo cost?
Trial Friend does not list a price for Mimrylo. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Drugmaker help: MIMRYLO Patient Support (Takeda Oncology Here2Assist).
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Mimrylo decision?
The FDA approved Mimrylo for Polycythemia vera on August 28, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from Takeda press release. This page rechecks against our calendar, which is re-verified daily.